Current United States Preventative Services Task Force (USPSTF) guidelines endorse
shared decision making (SDM) for PSA screening.
1
However, current evidence shows marked variation and underutilization in SDM for
prostate cancer screening, especially amongst more vulnerable patient populations.
2
Although poorly studied, race and ethnicity, levels of education, income, and health
literacy likely all play an important role in the adoption of SDM and, hence, account
at least in part for the discrepancy between guideline recommendations and current
practice.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.Cancer. 2018; 124: 2733-2739
- Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline.Prostate Cancer Prostatic Dis. 2021; 24: 77-80
- Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.Cancer. 2021; 127: 249-256
- Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers.Trials. 2021; 22: 128
Article info
Publication history
Accepted:
May 2,
2021
Received:
January 22,
2021
Identification
Copyright
© 2021 Published by Elsevier Inc.
